Annual Accounts Receivable
$53.51 M
+$43.08 M+412.64%
31 December 2023
Summary:
Catalyst Pharmaceuticals annual accounts receivable is currently $53.51 million, with the most recent change of +$43.08 million (+412.64%) on 31 December 2023. During the last 3 years, it has risen by +$47.53 million (+793.84%). CPRX annual accounts receivable is now at all-time high.CPRX Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Receivable
$58.27 M
+$1.09 M+1.91%
30 September 2024
Summary:
Catalyst Pharmaceuticals quarterly accounts receivable is currently $58.27 million, with the most recent change of +$1.09 million (+1.91%) on 30 September 2024. Over the past year, it has increased by +$10.22 million (+21.26%). CPRX quarterly accounts receivable is now -3.68% below its all-time high of $60.49 million, reached on 31 March 2024.CPRX Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CPRX Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +412.6% | +21.3% |
| 3 y3 years | +793.8% | +779.5% |
| 5 y5 years | +100.0% | +477.1% |
CPRX Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +793.8% | -3.7% | +780.3% |
| 5 y | 5 years | at high | -3.7% | +940.3% | |
| alltime | all time | at high | -3.7% |
Catalyst Pharmaceuticals Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $58.27 M(+1.9%) |
| June 2024 | - | $57.17 M(-5.5%) |
| Mar 2024 | - | $60.49 M(+13.0%) |
| Dec 2023 | $53.51 M(+412.6%) | $53.51 M(+11.4%) |
| Sept 2023 | - | $48.05 M(+12.3%) |
| June 2023 | - | $42.80 M(+28.1%) |
| Mar 2023 | - | $33.40 M(+220.0%) |
| Dec 2022 | $10.44 M(+57.7%) | $10.44 M(+11.8%) |
| Sept 2022 | - | $9.34 M(-2.6%) |
| June 2022 | - | $9.59 M(-9.1%) |
| Mar 2022 | - | $10.55 M(+59.4%) |
| Dec 2021 | $6.62 M | $6.62 M(-0.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2021 | - | $6.63 M(+5.3%) |
| June 2021 | - | $6.29 M(+12.3%) |
| Mar 2021 | - | $5.60 M(-6.4%) |
| Dec 2020 | $5.99 M(-43.2%) | $5.99 M(+2.0%) |
| Sept 2020 | - | $5.87 M(-13.2%) |
| June 2020 | - | $6.76 M(-2.3%) |
| Mar 2020 | - | $6.92 M(-34.3%) |
| Dec 2019 | $10.54 M(>+9900.0%) | $10.54 M(+4.4%) |
| Sept 2019 | - | $10.10 M(-2.7%) |
| June 2019 | - | $10.38 M(+43.1%) |
| Mar 2019 | - | $7.25 M(>+9900.0%) |
| Dec 2018 | $0.00 | $0.00 |
FAQ
- What is Catalyst Pharmaceuticals annual accounts receivable?
- What is the all time high annual accounts receivable for Catalyst Pharmaceuticals?
- What is Catalyst Pharmaceuticals annual accounts receivable year-on-year change?
- What is Catalyst Pharmaceuticals quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Catalyst Pharmaceuticals?
- What is Catalyst Pharmaceuticals quarterly accounts receivable year-on-year change?
What is Catalyst Pharmaceuticals annual accounts receivable?
The current annual accounts receivable of CPRX is $53.51 M
What is the all time high annual accounts receivable for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals all-time high annual accounts receivable is $53.51 M
What is Catalyst Pharmaceuticals annual accounts receivable year-on-year change?
Over the past year, CPRX annual accounts receivable has changed by +$43.08 M (+412.64%)
What is Catalyst Pharmaceuticals quarterly accounts receivable?
The current quarterly accounts receivable of CPRX is $58.27 M
What is the all time high quarterly accounts receivable for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals all-time high quarterly accounts receivable is $60.49 M
What is Catalyst Pharmaceuticals quarterly accounts receivable year-on-year change?
Over the past year, CPRX quarterly accounts receivable has changed by +$10.22 M (+21.26%)